Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with inluenza: An open-label, single-arm study

Antiviral Therapy

Volumn 20, Issue 4, 2015, Pages 415-423

  Watanabe, Akira ^a   Yates, Phillip J ^b   Murayama, Marie ^c   Soutome, Toru ^c   Furukawa, Hiroiku ^c  

^a TOHOKU UNIVERSITY   (Japan)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Development and Medical Affairs Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CONSTIPATION; DECUBITUS; DELIRIUM; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HEMORRHOID; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOKALEMIA; INFLUENZA A (H3N2); INFLUENZA B; INJECTION SITE REACTION; INSOMNIA; JAPANESE (PEOPLE); MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RASH; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SYMPTOM; UPPER ABDOMINAL PAIN; VERY ELDERLY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATIENT SAFETY; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEURAMINIDASE; PATIENT SAFETY; TREATMENT OUTCOME; VIRAL PROTEINS; ZANAMIVIR;

EID: 84947564573     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2922     Document Type: Article

References (25)

1. Department of Health and Human Services. HHS pandemic inluenza plan. 2005. (Accessed December 2012.) Available from http://www.lu.gov/planning-preparedness/federal/ hhspandemicinluenzaplan.pdf
2. World Health Organization. Transmission dynamics and impact of pandemic inluenza A (H1N1) 2009 virus. Wkly Epidemiol Rec 2009; 84:481-484.
3. Webster RG, Govorkova EA. H5N1 inluenza-continuing evolution and spread. N Engl J Med 2006; 355:2174-2177.
4. National Institute of Infectious Diseases. Risk assessment and management of cases of human infection with avian inluenza A(H7N9) virus in China. (Accessed April 18 2013.) Available from http://www.nih.go.jp/niid/en/lu-m/ lutoppage/2276-lu2013h7n9/a-h7n9-niid/3487-riskassess-130418-en.html
5. Chen H, Yuan H, Gao R, et al. Clinical and epidemiological characteristics of a fatal case of avian inluenza A H10N8 virus infection: a descriptive study. Lancet 2014; 383:714-721.
6. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among inluenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:8026.
7. Baranovich T, Saito R, Suzuki Y, et al. Emergence of H274Y oseltamivir-resistant A(H1N1) inluenza viruses in Japan during the 2008-2009 season. J Clin Virol 2010; 47:23-28.
8. Tamilu® (oseltamivir phosphate). Package insert 2013. Genentech USA, Inc., South San Francisco, CA, USA.
9. Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of inluenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167-1175.
10. Sugaya N, Kohno S, Ishibashi T, et al. Eficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 inluenza A virus infection. Antimicrob Agents Chemother 2012; 56:369-377.
11. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant inluenza virus neuraminidase mutants. Nature 2008; 453:1258-1261.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
13. Joy MS, Matzke GR, Armstrong DK, et al. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998; 32:362-375.
14. National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004. (Accessed February 2013.) Available from http://www. niaid.nih.gov/labsandresources/resources/daidsclinrsrch/ documents/daidsaegradingtable.pdf
15. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase Inhibitor resistance in inluenza viruses and laboratory testing methods. Antivir Ther 2012; 17:159-173.
16. Tisdale M. Inluenza M2 ion-channel and neuraminidase inhibitors. In Mayers DL (editor). Antimicrobial drug resistance: mechanisms of drug resistance. New York: Humana Press 2009; pp. 421-447.
17. CDC. Report May 5, 2009 Interim Guidance for Clinicians on Identifying and Caring for Patients with Swine-origin Inluenza A (H1N1) Virus Infection. (Accessed 29 April 2009.) Available from http://idsc.nih.go.jp/disease/swine- inluenza/2009cdc/CDC-guidance.html
18. CDC. Hospitalized patients with novel inluenza A (H1N1) virus infection-California, April-May, 2009. Morbidity and Mortality Weekly Report (MMWR) Vol 58/May 22, 2009. (Accessed 22 May 2009.) Available from http://www. cdc.gov/mmwr/preview/mmwrhtml/mm58e0518a1.htm
19. Novel Swine-Origin Inluenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, et al. Emergence of a novel swine-origin inluenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-2615.
20. Novel Inluenza Countermeasures Committee, Japanese Association for Infectious Diseases. Urgent Proposal by the Japanese Association for Infectious Diseases 'Indication for use of anti-inluenza agents. Revised edition.' February 28, 2011. Japanese. (Accessed 28 February 2011.) Available from http://www.kansensho.or.jp/inluenza/110301soiv-teigen.html
21. Marty FM, Man CY, van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with inluenza: an open-label, multicenter, single-arm, Phase II study. J Infect Dis 2014; 209:542-550.
22. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of inluenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-2272.
23. Puzelli S, Facchini M, Di Martino A, et al. Evaluation of the antiviral drug susceptibility of inluenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. Antiviral Res 2011; 90:205-212.
24. Barnett JM, Cadman A, Burrell FM, et al. In vitro selection and characterisation of inluenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265:286-295.
25. Gor D, Cadman A, Dempsey M, et al. Antiviral eficacy and sequence analysis of the HA and NA genes of inluenza isolates from zanamivir Phase II/III clinical eficacy trials. 39th ICAAC. 26-29 September 1999, San Francisco, CA, USA. Abstract/Poster 284.